Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Hum Vaccin Immunother ; 11(3): 584-600, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25715048

RESUMEN

Efforts to develop vaccines for prevention of acute diarrhea have been going on for more than 40 y with partial success. The myriad of pathogens, more than 20, that have been identified as a cause of acute diarrhea throughout the years pose a significant challenge for selecting and further developing the most relevant vaccine candidates. Based on pathogen distribution as identified in epidemiological studies performed mostly in low-resource countries, rotavirus, Cryptosporidium, Shigella, diarrheogenic E. coli and V. cholerae are predominant, and thus the main targets for vaccine development and implementation. Vaccination against norovirus is most relevant in middle/high-income countries and possibly in resource-deprived countries, pending a more precise characterization of disease impact. Only a few licensed vaccines are currently available, of which rotavirus vaccines have been the most outstanding in demonstrating a significant impact in a short time period. This is a comprehensive review, divided into 2 articles, of nearly 50 vaccine candidates against the most relevant viral and bacterial pathogens that cause acute gastroenteritis. In order to facilitate reading, sections for each pathogen are organized as follows: i) a discussion of the main epidemiological and pathogenic features; and ii) a discussion of vaccines based on their stage of development, moving from current licensed vaccines to vaccines in advanced stage of development (in phase IIb or III trials) to vaccines in early stages of clinical development (in phase I/II) or preclinical development in animal models. In this first article we discuss rotavirus, norovirus and Vibrio cholerae. In the following article we will discuss Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic), and Campylobacter jejuni.


Asunto(s)
Vacunas contra el Cólera/inmunología , Diarrea/prevención & control , Gastroenteritis/prevención & control , Vibrio cholerae/inmunología , Vacunas Virales/inmunología , Virus/inmunología , Ensayos Clínicos como Asunto , Diarrea/epidemiología , Diarrea/microbiología , Diarrea/virología , Aprobación de Drogas , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Gastroenteritis/epidemiología , Gastroenteritis/microbiología , Gastroenteritis/parasitología , Gastroenteritis/virología , Humanos
2.
Hum Vaccin Immunother ; 11(3): 601-19, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25715096

RESUMEN

In Part II we discuss the following bacterial pathogens: Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic) and Campylobacter jejuni. In contrast to the enteric viruses and Vibrio cholerae discussed in Part I of this series, for the bacterial pathogens described here there is only one licensed vaccine, developed primarily for Vibrio cholerae and which provides moderate protection against enterotoxigenic E. coli (ETEC) (Dukoral(®)), as well as a few additional candidates in advanced stages of development for ETEC and one candidate for Shigella spp. Numerous vaccine candidates in earlier stages of development are discussed.


Asunto(s)
Vacunas Bacterianas/inmunología , Campylobacter jejuni/inmunología , Diarrea/prevención & control , Escherichia coli/inmunología , Gastroenteritis/prevención & control , Salmonella/inmunología , Shigella/inmunología , Ensayos Clínicos como Asunto , Diarrea/epidemiología , Diarrea/microbiología , Diarrea/virología , Aprobación de Drogas , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Gastroenteritis/epidemiología , Gastroenteritis/microbiología , Gastroenteritis/parasitología , Gastroenteritis/virología , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA